Early detection of endothelial dysfunction and early therapeutic correction effectively restore renal function in type 2 diabetic nephropathy.
Futrakul
Narisa
N
Butthep
P
P
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D003928:Diabetic Nephropathies / Q000175:diagnosis* / Q000188:drug therapy* / Q000517:prevention & control; D042783:Endothelial Cells / Q000166:cytology* / Q000502:physiology; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007677:Kidney Function Tests; D008297:Male; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents